|
1
|
Esteller M: Epigenetics in cancer. N Engl
J Med. 358:1148–1159. 2008.
|
|
2
|
Kang GH: CpG island hypermethylation in
gastric carcinoma and its premalignant lesions. Korean J Pathol.
46:1–9. 2012.
|
|
3
|
Esteller M, Com PG, Baylin SB and Herman
JG: A gene hypermethylation profile of human cancer. Cancer Res.
61:3225–3229. 2001.
|
|
4
|
Suzuki H, Watkins DN, Jair KW, et al:
Epigenetic inactivation of SFRP genes allows constitutive WNT
signaling in colorectal cancer. Nat Genet. 36:417–422. 2004.
|
|
5
|
Ushijima T: Detection and interpretation
of altered methylation patterns in cancer cells. Nat Rev Cancer.
5:223–231. 2005.
|
|
6
|
Tsuchiya T, Sekine K, Hinohara S, Namiki
T, Nobori T and Kaneko Y: Analysis of the p16INK4, p14ARF, p15,
TP53, and MDM2 genes and their prognostic implications in
osteosarcoma and Ewing sarcoma. Cancer Genet Cytogenet. 120:91–98.
2000.
|
|
7
|
Hoque MO, Kim MS, Ostrow KL, et al:
Genome-wide promoter analysis uncovers portions of the cancer
methylome. Cancer Res. 68:2661–2670. 2008.
|
|
8
|
Bibikova M, Lin Z, Zhou L, et al:
High-throughput DNA methylation profiling using universal bead
arrays. Genome Res. 16:383–393. 2006.
|
|
9
|
Lin Z, Thomas NJ, Bibikova M, et al: DNA
methylation markers of surfactant proteins in lung cancer. Int J
Oncol. 31:181–191. 2007.
|
|
10
|
Bibikova M, Chudin E, Wu B, et al: Human
embryonic stem cells have a unique epigenetic signature. Genome
Res. 16:1075–1083. 2006.
|
|
11
|
Bjornsson HT, Brown LJ, Fallin MD, et al:
Epigenetic specificity of loss of imprinting of the IGF2 gene in
Wilms tumors. J Natl Cancer Inst. 99:1270–1273. 2007.
|
|
12
|
de Alvia E, Lessnick SL and Sorensen PH:
Ewing sarcoma. WHO Classification of Tumors of Soft Tissue and
Bone. Fletcher CDM, Bridge JA, Hogendoorn PCW and Mertens F: IARC
Press; Lyon: pp. 305–310. 2013
|
|
13
|
Kim GY, Park JH, Kim YW, Jung WW, Unni KK
and Park YK: Absence of amplification of HER-2/neu (c-erbB-2) gene
in Ewing’s sarcoma: a real-time polymerase chain reaction method.
Pathol Res Pract. 200:663–667. 2004.
|
|
14
|
Farrand K, Jovanovic L, Delahunt B, et al:
Loss of heterozygosity studies revisited: prior quantification of
the amplifiable DNA content of archival samples improves efficiency
and reliability. J Mol Diagn. 4:150–158. 2002.
|
|
15
|
Bibikova M and Fan JB: GoldenGate assay
for DNA methylation profiling. Methods Mol Biol. 507:149–163.
2009.
|
|
16
|
Khoury JD: Ewing sarcoma family of tumors.
Adv Anat Pathol. 12:212–220. 2005.
|
|
17
|
Fulda S, Küfer MU, Meyer E, van Valen F,
Dockhorn-Dworniczak B and Debatin KM: Sensitization for death
receptor- or drug-induced apoptosis by re-expression of caspase-8
through demethylation or gene transfer. Oncogene. 20:5865–5877.
2001.
|
|
18
|
López-Guerrero JA, Pellín A, Noguera R,
Carda C and Llombart-Bosch A: Molecular analysis of the 9p21 locus
and p53 genes in Ewing family tumors. Lab Invest. 81:803–814.
2001.
|
|
19
|
Rathi A, Virmani AK, Harada K, et al:
Aberrant hypermethylation of the HIC1 promoter is a frequent event
in specific pediatric neoplasms. Clin Cancer Res. 9:3674–3678.
2003.
|
|
20
|
Martín-Subero JI, Kreuz M, Bibikova M, et
al; Molecular Mechanisms in Malignant Lymphomas Network Project of
the Deutsche Krebshilfe. New insights into the biology and origin
of mature aggressive B-cell lymphomas by combined epigenomic,
genomic, and transcriptional profiling. Blood. 113:2488–2497.
2009.
|
|
21
|
Serao NV, Delfino KR, Southey BR, Beever
JE and Rodriguez-Zas SL: Cell cycle and aging, morphogenesis, and
response to stimuli genes are individualized biomarkers of
glioblastoma progression and survival. BMC Med Genomics.
4:492011.
|
|
22
|
Giovannini M, Selleri L, Hermanson GG and
Evans GA: Localization of the human oncostatin M gene (OSM) to
chromosome 22q12, distal to the Ewing’s sarcoma breakpoint.
Cytogenet Cell Genet. 62:32–34. 1993.
|
|
23
|
Weiss TW, Simak R, Kaun C, et al:
Oncostatin M and IL-6 induce u-PA and VEGF in prostate cancer cells
and correlate in vivo. Anticancer Res. 31:3273–3278. 2011.
|
|
24
|
Ignatov A, Bischoff J, Ignatov T, et al:
APC promoter hypermethylation is an early event in endometrial
tumorigenesis. Cancer Sci. 101:321–327. 2010.
|
|
25
|
Shu Y, Wang B, Wang J, Wang JM and Zou SQ:
Identification of methylation profile of HOX genes in extrahepatic
cholangiocarcinoma. World J Gastroenterol. 17:3407–3419. 2011.
|
|
26
|
Fiegl H, Windbichler G, Mueller-Holzner E,
et al: HOXA11 DNA methylation - a novel prognostic biomarker in
ovarian cancer. Int J Cancer. 123:725–729. 2008.
|
|
27
|
Avigad S, Shukla S, Naumov I, et al:
Aberrant methylation and reduced expression of RASSF1A in Ewing
sarcoma. Pediatr Blood Cancer. 53:1023–1028. 2009.
|
|
28
|
Harada K, Toyooka S, Maitra A, et al:
Aberrant promoter hypermethylation and silencing of the RASSF1A
gene in pediatric tumors and cell lines. Oncogene. 21:4345–4349.
2002.
|
|
29
|
Garcia-Manero G: Demethylating agents in
myeloid malignancies. Curr Opin Oncol. 20:705–710. 2008.
|
